Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown. OBJECTIVE: To determine...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA
Main Authors: Venook, Alan P., Niedzwiecki, Donna, Lenz, Heinz-Josef, Innocenti, Federico, Fruth, Briant, Meyerhardt, Jeffrey A., Schrag, Deborah, Greene, Claire, O’Neil, Bert H., Atkins, James Norman, Berry, Scott, Polite, Blase N., O’Reilly, Eileen M., Goldberg, Richard M., Hochster, Howard S., Schilsky, Richard L., Bertagnolli, Monica M., El-Khoueiry, Anthony B., Watson, Peter, Benson, Al B., Mulkerin, Daniel L., Mayer, Robert J., Blanke, Charles
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5545896/
https://ncbi.nlm.nih.gov/pubmed/28632865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2017.7105
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados